Ke Peng
Impact in
- Pharmaceutical Science top 0.2%
- Advancements in Transdermal Drug Delivery
- Advanced Drug Delivery Systems
- Virology top 2%
- HIV Research and Treatment
Papers in
-
- Viral Infections and Vectors 12
- HIV/AIDS drug development and treatment 8
- Co-authors
- Alexander Kros (6 shared papers)Itsuro Tomatsu (6 shared papers)Zhong Zhang (3 shared papers)Ryan F. Donnelly (20 shared papers)Lalitkumar K. Vora (19 shared papers)Shufen Li (12 shared papers)Ismaiel A. Tekko (9 shared papers)Luqi Liu (3 shared papers)
- Journals
- International Journal of Pharmaceutics (7 papers)Journal of Virology (6 papers)ACS Applied Materials & Interfaces (4 papers)Journal of Controlled Release (4 papers)ACS Applied Bio Materials (3 papers)
- Partner nations
- ChinaUnited KingdomNetherlands
In The Last Decade
Ke Peng
151 papers receiving 5.6k citations
Ke Peng's Hit Papers
Peers
Comparison fields: 5 of 170
- Pharmaceutical Science 953
- Virology 379
- Molecular Medicine 376
- Biomaterials 707
- Infectious Diseases 972
Countries citing papers authored by Ke Peng
This map shows the geographic impact of Ke Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ke Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ke Peng more than expected).
Fields of papers citing papers by Ke Peng
This network shows the impact of papers produced by Ke Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ke Peng. The network helps show where Ke Peng may publish in the future.
Co-authors
The 25 scholars most cited alongside Ke Peng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 156 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 437 | |
| 2 | 2011 | 317 | |
| 3 | 2020 | 254 | |
| 4 | Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension Hit paper breakdown → | 2020 | 233 |
| 5 | 2020 | 215 | |
| 6 | 2010 | 205 | |
| 7 | 2011 | 198 | |
| 8 | 2017 | 184 | |
| 9 | 2019 | 141 | |
| 10 | 2014 | 131 | |
| 11 | 2020 | 115 | |
| 12 | 2020 | 112 | |
| 13 | 2021 | 105 | |
| 14 | 2011 | 100 | |
| 15 | 2020 | 91 | |
| 16 | 2021 | 90 | |
| 17 | 2010 | 85 | |
| 18 | 2009 | 75 | |
| 19 | 2019 | 73 | |
| 20 | 2017 | 73 |
About Ke Peng
Ke Peng is a scholar working on Molecular Biology, Infectious Diseases, Immunology, Pharmaceutical Science and Materials Chemistry, having authored 156 papers that have together received 5.6k indexed citations. Recurring topics across this work include Advancements in Transdermal Drug Delivery (17 papers), Advanced Drug Delivery Systems (13 papers), Viral Infections and Vectors (12 papers), Dermatology and Skin Diseases (10 papers), interferon and immune responses (9 papers), HIV Research and Treatment (8 papers), HIV/AIDS drug development and treatment (8 papers) and Supramolecular Self-Assembly in Materials (8 papers). The work is most often cited by research in Pharmaceutical Science (953 citations), Virology (379 citations), Molecular Medicine (376 citations), Biomaterials (707 citations) and Infectious Diseases (972 citations). Ke Peng has collaborated with scholars based in China, United Kingdom and Netherlands. Frequent co-authors include Alexander Kros, Itsuro Tomatsu, Zhong Zhang, Ryan F. Donnelly, Lalitkumar K. Vora, Shufen Li, Ismaiel A. Tekko, Luqi Liu, Xinglong Gong and Yu Jia. Their work appears in journals such as International Journal of Pharmaceutics, Journal of Virology, ACS Applied Materials & Interfaces, Journal of Controlled Release and ACS Applied Bio Materials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.